Related Experiment Video
Updated: Jun 8, 2026

Membrane Potential Dye Imaging of Ventromedial Hypothalamus Neurons From Adult Mice to Study Glucose Sensing
Published on: November 27, 2013
High glucose and renin release: the role of succinate and GPR91
1Departments of Physiology and Biophysics, and Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California, USA. petipete@usc.edu
Abstract:
Diabetes mellitus is the most common and rapidly growing cause of end-stage renal disease. A classic hallmark of diabetes pathology is the activation of the intrarenal renin-angiotensin system (RAS), which may lead to hypertension and renal tissue injury, but the mechanism of RAS activation has been elusive. Recently, we described the intrarenal localization of the novel metabolic receptor GPR91 and established some of its functions in diabetes. These include the triggering of renin release in early diabetes via both vascular (endothelial) and tubular (macula densa) sites in the juxtaglomerular apparatus as well as the activation of MAP kinases in the distal nephron-collecting duct, which are important signaling mechanisms in diabetic nephropathy (DN) and renal fibrosis. GPR91 is a cell surface receptor for succinate and during the past few years it has provided a new paradigm for the mechanism of cell stress response in many organs. Beyond its traditional role in the tricarboxylic acid cycle, succinate now has an unexpected hormone-like signaling function, which may provide a feedback between local tissue metabolism, mitochondrial stress, and organ functions. Succinate accumulation in the local tissue environment and GPR91 signaling appear to be important early mechanisms by which cells detect and respond to hyperglycemia and trigger tissue injury in DN. Also, the distal nephron-collecting duct system, which is the major source of (pro)renin in diabetes and has the highest level of GPR91 expression in the kidney, may have an important, active, and early role in the pathogenesis of DN in contrast to the existing glomerulus-centric paradigm.
Insights
The GPR91 receptor, activated by succinate, plays a key role in early diabetes, triggering renin release and kidney injury. This discovery shifts focus to the distal nephron
Area of Science:
- Nephrology
- Endocrinology
- Metabolic Research
Background:
- Diabetes mellitus is a leading cause of end-stage renal disease.
- Intrarenal renin-angiotensin system (RAS) activation is a hallmark of diabetic kidney pathology, but its mechanism is unclear.
- The novel metabolic receptor GPR91 has been identified within the kidney.
Purpose of the Study:
- To investigate the role of the GPR91 receptor in the pathogenesis of diabetic nephropathy (DN).
- To elucidate the mechanism of RAS activation in early diabetes.
- To explore the function of GPR91 in triggering renin release and renal tissue injury.
Main Methods:
- Investigated intrarenal GPR91 localization and function in diabetes.
- Examined GPR91's role in renin release from vascular and tubular sites.
- Assessed MAP kinase activation in the distal nephron-collecting duct.
Main Results:
- GPR91 is localized within the kidney and mediates renin release in early diabetes.
- GPR91 activation triggers MAP kinase signaling in the distal nephron-collecting duct, contributing to DN.
- Succinate accumulation and GPR91 signaling are early responses to hyperglycemia, promoting renal injury.
Conclusions:
- GPR91 is a crucial sensor of hyperglycemia and a mediator of early diabetic kidney injury.
- The distal nephron-collecting duct, expressing high GPR91 levels, plays an active role in DN pathogenesis.
- This challenges the traditional glomerulus-centric view of diabetic nephropathy.
Related Concept Videos
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GPCR Desensitization
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Secondary Active Transport
